ProMIS Neurosciences Inc
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ProMIS Neurosciences' stock, predicting a significant price increase potential.
Financial Health
ProMIS Neurosciences is generating solid cash flow and has a good book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PMN
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketPotential Bargains
These companies are trading below what experts believe they're truly worth. Our analysts have carefully selected stocks with significant upside potential, representing hidden opportunities for growth as they move toward their projected valuations.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Selective antibody approach
ProMIS targets misfolded, disease‑linked proteins to limit off‑target effects — a technically differentiated strategy, though outcomes depend on clinical validation.
Clinical catalysts to watch
Trial readouts, regulatory updates and partnership deals can be major share‑price drivers; be aware these are binary and can cause sharp moves.
Small‑cap considerations
With a market cap around $23.7m, the stock can be illiquid and volatile; suitable mainly for investors who accept higher risk and potential dilution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
